Table 2.
Proliferation of PBMC from HSV-patients at different disease stages in response to HSV antigens
| Disease stage | No. samples/no. patients S/P | Responders S/P | Non-Responders S/P | SI toαCD3 Ab* | SI to HSV-1* | SI to HSV-2* | |||
|---|---|---|---|---|---|---|---|---|---|
| Active disease | 26/21 | 22/17 | 4/4 | R: | 122·9 ± 22·2 | R: | 6·4 ± 0·9 | R: | 7·7 ± 1·3 |
| NR: | 77·3 ± 32·7 | NR: | 1·3 ± 0·4 | NR: | 1·2 ± 0·1 | ||||
| Non-active disease | 28/12 | 22/10 | 6/2 | R: | 76·4 ± 13·7 | R: | 21·2 ± 6·1 | R: | 10·0 ± 1·9 |
| NR: | 157·0 ± 64·3 | NR: | 3·3 ± 0·6 | NR: | 1·2 ± 0·2 | ||||
| Asymptomatic | |||||||||
| Seropositive | 7/7 | 3/3 | 4/4 | ND | ND | R: | 75·6 ± 32·2 | ||
| NR: | 2·3 ± 0·6 | ||||||||
| Seronegative | 7/6 | 0 | 7/6 | NR: | 45·6 ± 5·9 | NR: | 1·3 ± 0·2 | NR: | 1·0 ± 0·2 |
PBMC (1 × 106/ml) were stimulated with αCD3 antibodies (1:200 final dilution of culture supernatant of αCD3 monoclonal antibody hybridoma), HSV-1 or HSV-2 antigens. PBMC were classified as responders (R) and nonresponders (NR) on the basis of proliferative responses to HSV-2 antigen: R, Stimulation Index (SI) > 3; NR, SI < 3.
*
Mean ± SEM. ND, not done